跳至主要内容
临床试验/NCT00960089
NCT00960089已完成不适用

Evaluation of the Efficacy of Chesson Labs LIQUICURE™ for Treatment of Onychomycosis

Chesson Laboratory Associates, Inc4 个研究点 分布在 1 个国家目标入组 63 人开始时间: 2008年7月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
63
试验地点
4
主要终点
Freedom from major product-related adverse events for the duration of the feasibility phase.

研究概览

简要总结

There is a major clinical need for an inexpensive topically-applied product that can inhibit the growth of the dermatophytes that cause nail fungus. Chesson Labs has developed LIQUICURE with a longer drying/curing time that will allow better nail penetration or adsorption. Though the product may have inherent antimicrobial activity, the product does not contain a drug or antimicrobial agent.

Consistent use of LIQUICURE as described will clear fungal nail infection. Clearing of nail fungal infection is defined by negative dermatophyte culture and visual improvement in nail characteristics within six months, with few, if any product-related adverse events.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Nail fungal infection of at least one great toe [per visual assessment, positive KOH preparation, and positive dermatophyte culture]
  • •Subjects who have target toenail showing 20-65% involvement as judged by the clinical investigator
  • •2 mm of clear nail proximally on great toenail / no lunula involvement
  • •Subject must be physically able to reach toes to clean them and apply product
  • •Subject is willing to discontinue use of other nail fungus treatment products and nail cosmetic products for duration of this study
  • •Subject is willing and available to return for study follow up
  • •Ability of the subject or legal representative to understand and provide signed consent for participating in the study
  • •Negative urine pregnancy test for women of child bearing age
  • •Females must be post menopausal or must agree to use approved contraceptives (actions, devices or medications to prevent or reduce the likelihood of pregnancy) throughout the study (Note: abstinence is NOT an accepted form of contraception)

排除标准

  • •Known hypersensitivity or allergy to the product materials
  • •Negative KOH preparation or dermatophyte culture
  • •Thickness of nail greater than 3 mm
  • •Enrollment in another investigational drug or product protocol that would interfere with this study
  • •Continuation or use of other topical or pharmaceutical treatments for the condition; a wash-out period of at least four weeks after discontinuation of a topical product or 180 days after discontinuation of an oral product for treatment of nail fungus is required
  • •Chronic disease, including: diabetes, psoriasis, immune deficiency, severe foot injury, chronic vascular disease or any other condition that would decrease circulation to the extremities at the discretion of the investigator Pregnant or nursing females
  • •Investigators, Chesson personnel, or Chesson Scientific Advisory Board members or their immediate family

研究组 & 干预措施

LIQUICURE

Experimental

Medical Device

干预措施: LIQUICURE (Device)

结局指标

主要结局

Freedom from major product-related adverse events for the duration of the feasibility phase.

时间窗: Six months

Clearance of fungal nail infection defined by negative culture and improvement in visual nail characteristics

时间窗: Six months

次要结局

  • Time to clearance of infection(6 months)

研究者

发起方
Chesson Laboratory Associates, Inc
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验